Chemosensitizing AML cells by targeting bone marrow endothelial cells.

Area of Science:

• Hematology
• Oncology
• Vascular Biology

Background:

• Refractory acute myeloid leukemia (AML) presents a significant therapeutic challenge.
• Blood vessels within the bone marrow microenvironment may act as protective sanctuaries for AML cells.
• Bone marrow endothelial cells (BMECs) play a role in maintaining AML cell quiescence.

Purpose of the Study:

• To investigate the role of BMECs in protecting AML cells.
• To evaluate the efficacy of targeting BMECs with combretastatins in combination with chemotherapy.
• To explore a novel therapeutic strategy for refractory AML.

Main Methods:

• Co-culture of AML cells with BMECs.
• Treatment of co-cultures with tubulin-binding combretastatins.
• Assessment of BMEC phenotype, adhesion molecule expression, and AML cell cycle status.
• In vivo studies using mice xenograft models.

Main Results:

• Combretastatins altered BMEC morphology and reduced adhesion molecule expression (VCAM-1, VE-cadherin).
• Combretastatins treatment dislodged AML cells from BMECs and promoted cell cycle progression.
• Combination therapy with combretastatins and cytotoxic chemotherapy resulted in enhanced AML cell death.
• Complete AML regression was observed in mice treated with the combination therapy.

Conclusions:

• BMECs contribute to AML resistance by providing a protective niche.
• Vascular-targeting agents like combretastatins can disrupt this protective niche.
• Combination therapy of combretastatins and chemotherapy offers a promising strategy for treating refractory AML.